{"texts": ["Algorithm 1. Initial Management (0-12 hours)\nReassess patient and response to fluids within 4-6 hours: \nVitals, Urine output, and Fluid status (avoid fluid overload)\nCopyright \u00a92011. The Ohio State University. All rights reserved. This document may be used for noncommercial educational and \nnoncommercial (NOT funded by a commercial entity) research use only. OSUWMC Clinical Practice Guidelines may not be reproduced, \ndisplayed, modified, or distributed in any form without a written agreement with The Ohio State University Technology Commercialization \nOffice. Requests can be directed to Technology Commercialization Office (TCO) or email innovate@osu.edu\nPatient presents with signs and symptoms consistent with acute pancreatitis\nOSUWMC Clinical Practice Guideline\nApril 2022\nManagement of Acute Pancreatitis (AP)\n What You Need to Know\n\u25aa Serial monitoring of amylase and lipase levels is not recommended due to lack of correlation with clinical progress or prognosis.\n\u25aa Early IV fluids are key for symptom control and prevention of pancreatic necrosis.\n\u25aa Obtain RUQ U/S when gallstone pancreatitis is suspected.\n\u25aa CT is NOT required for diagnosis, and may be misleading in early stages of pancreatitis. \n\u25aa Prophylactic antibiotics are NOT routinely recommended.\nCharacteristic epigastric abdominal pain AND Amylase \nor lipase \u2265 3x upper limit of normal (ULN)\nAcute pancreatitis confirmed\nManagement\nSee page 2 for appropriate level of care 12-72 hours after admission\nGoals Met? \n\u25aa Decrease in heart rate\n\u25aa Urine output > 0.5 mL/kg/hr\n\u25aa Decrease in BUN\n\u25aa Decrease in HCT\n\u25aa Continue 1.5 mL/kg/hr.\n\u25aa Consider repeat bolus of 10 mL/kg in case of urine output < 0.5 mL/kg/hr or systemic BP < 90 mmHg.\nNO\n\u25aa AVOID using CT unless the diagnosis is uncertain as it may be \nmisleading in the early stage of disease.\n\u25aa RUQ U/S is recommended for patients with suspected gallstone \npancreatitis (intact gallbladder, abnormal LFTs).\n\u25aa See page 3 for other imaging indications and guidelines. \n\u25aa 10 mL/kg bolus in patients with hypovolemia (i.e., \napproximately 700 mL for 70 kg) or no bolus in patients with \nnormovolemia.\n\u25aa Then 1.5 mL/kg/hr (i.e. 100 mL/hr for 70 kg).\n\u25aa LR preferred, but avoid in patients with hypercalcemia. \n\u25aa Use with caution in those with history of heart failure or \nrespiratory disease.\nEarly Moderate IV Fluids\n\u25aa Encourage early patient-directed oral intake.\n\u25aa Consider non-opioid adjunctive analgesia (i.e., scheduled \nacetaminophen 975 mg every 6 hours and scheduled \nondansetron 4 mg every 6 hours for the initial 24 hrs.). \n\u25aa Consider as-needed parenteral analgesia for mild to moderate \npain (i.e., ketorolac 15-30 mg) and severe pain (i.e., morphine or \nhydromorphone).\n\u25aa Encourage early ambulation.\nSymptom Control\n\u25aa BUN, HCT, LFTs, triglyceride (TG), calcium, C-reactive protein\nImaging\nLabs\nUse clinical judgement to determine \nneed for additional testing if both \ncriteria are not met, but there is still \nconcern for acute pancreatitis.\nIf symptoms are controlled or nearly \ncontrolled in ED, consider transfer to \nCDU/observation unit for fluids, PO \nchallenge, and early discharge.\n", "2 \nCopyright \u00a92021. The Ohio State University. All rights reserved. This document may be used for noncommercial educational and noncommercial (NOT funded by a commercial entity) research use only. OSUWMC Clinical \nPractice Guidelines may not be reproduced, displayed, modified, or distributed in any form without a written agreement with The Ohio State University Technology Commercialization Office. Requests can be directed \nto Technology Commercialization Office (TCO) or email innovate@osu.edu \nDetermine Clinical Severity to Guide Subsequent Management Consider comorbidities and pre-existing organ failure (i.e., CHF, CKD) \nAssessment Tool \nCriteria \nMild AP \nModerate / Severe AP \nBedside Index for Severity in \nAcute Pancreatitis (BISAP) \n\uf0a7\nBUN > 25 mg/dL\n\uf0a7 \nAltered mental status based on Glasgow Coma Scale (\u2264 5)\n\uf0a7 \nSystemic Inflammatory Response Syndrome Criteria (SIRS) \u2265 2\n\uf0a7\nAge > 60 years\n\uf0a7\nPleural effusion on CXR\n\u2264 2 \n> 3\n12-24 Hours Post Arrival\nMild AP \nModerate/Severe AP \nFluid Management \n\uf0a7\nDetermine volume status following resuscitation in emergency\nroom.\no\nGenerally, 10-20ml/kg initial bolus is sufficient\n\uf0a7\nEnsure fluid management goals are met: +\no\nUrine output > 0.5 mL/kg/hr\no\nDecrease in HCT and BUN from admission\n\uf0a7\n1.5 mL/kg/hr LR with PO as tolerated.\n\uf0a7\nIf suspicious for fluid overload, consider discontinuing or\ndecreasing IV fluids.\nNote: If SIRS is persistently \u2265 2 at 24 hours manage patient as \nsevere. \n\uf0a7\nDetermine volume status following resuscitation in emergency\nroom.\no\nGenerally, 10-20ml/kg initial bolus is sufficient\n\uf0a7\nEnsure fluid management goals are met: +\no\nUrine output > 0.5 mL/kg/hr\no\nDecrease in HCT and BUN from admission\n\uf0a7\nConsider additional bolus of 10 mL/kg LR if fluid management\ngoals are not met by 12 hours.\n\uf0a7\n1.5 mL/kg/hr LR with PO as tolerated.\n\uf0a7\nIf suspicious for fluid overload, consider discontinuing or\ndecreasing IV fluids. \nDiet/Nutrition \n\uf0a7\nEarly patient-directed oral feeding (starting with clear liquids is\nnot required)\n\uf0a7\nEarly patient-directed oral feeding (starting with clear liquids\nis not required)\n24-72 Hours Post Arrival\nMild AP \nModerate/Severe AP \nFluid Management \n\uf0a7\nContinue 1.5 mL/kg/hr until tolerating satisfactory oral intake \nto meet fluid requirements. \n\uf0a7 \nContinue 1.5 mL/kg/hr until tolerating satisfactory oral intake\nto meet fluid requirements.\nDiet/Nutrition \n\uf0a7\nEarly patient-directed oral feeding (starting with clear liquids is\nnot required)\n\uf0a7\nConsider NG if unable to take PO 48 hours after arrival. If\nunable to tolerate NG feeding, consider NJ and/or consultation\nwith Gastroenterology.\n\uf0a7\nEarly patient-directed oral feeding (starting with clear liquids\nis not required)\n\uf0a7\nConsider NG if unable to take PO 48 hours after arrival. If\nunable to tolerate NG feeding, consider NJ and/or\nconsultation with Gastroenterology.\n\uf0a7\nParenteral should generally be avoided but may be\nrecommended if unable to achieve nutritional targets with\nenteral nutrition.\nAntibiotics \n\uf0a7\nProphylactic antibiotics are NOT routinely recommended.\n\uf0a7\nProphylactic antibiotics are NOT routinely recommended. +\n\uf0a7\nConsider empiric antibiotics if suspected infection with clinical\ndecompensation.\n", "3 \n \nCopyright \u00a92021. The Ohio State University. All rights reserved. This document may be used for noncommercial educational and noncommercial (NOT funded by a commercial entity) research use only. OSUWMC Clinical \nPractice Guidelines may not be reproduced, displayed, modified, or distributed in any form without a written agreement with The Ohio State University Technology Commercialization Office. Requests can be directed \nto Technology Commercialization Office (TCO) or email innovate@osu.edu \n \n24-72 Hours Post Arrival \nMild AP \nModerate/Severe AP \nConsults \n\uf0a7 \nGastroenterology for questions regarding management. \nRoutine consult to GI is not required. \n\uf0a7 \nNutrition if placing feeding tube. \n\uf0a7 \nOutpatient GI referral (specify pancreas clinic) is recommended \nfor patients not evaluated by GI during the hospitalization. \n\uf0a7 \nAcute Care Surgery (ACS) if patient needs to be evaluated for \nsurgical intervention \n\uf0a7 \nGastroenterology for questions regarding management. \nRoutine consult to GI is not required. \n\uf0a7 \nAcute Care Surgery (ACS) if patient needs to be evaluated for \nsurgical intervention. \n\uf0a7 \nNutrition if placing feeding tube. \n\uf0a7 \nOutpatient GI referral is recommended for patients not \nevaluated by GI during the hospitalization. \nManagement of \nComplications  \n\uf0a7 \nThere is no utility in monitoring serial serum amylase or lipase after initial diagnosis.                \n\uf0a7 \nIf there is no clinical improvement by 72 hours, consider CT scan of the abdomen and pelvis with IV contrast. \n\uf0a7 \nAsymptomatic fluid collections do not require intervention regardless of size, location, or extension. \n\uf0a7 \nIf there is evidence of infected necrosis: \no \nStart antibiotics:  \n\uf0a7 \nSee OSUWMC Inpatient Infection by Site Antibiotic Grid \no \nDefer drainage 4\u22126 weeks to allow minimally invasive approach. + \n+Recommendations based on high quality evidence \n \nIndications for Imaging \nSee also: American College of Radiology ACR Appropriateness Criteria\u00ae Acute Pancreatitis \nRUQ US \nCT (IV contrast, PO \nunnecessary) \nMRI with contrast and MRCP \nEUS \nERCP \n\uf0a7 \nRecommended as the initial \nimaging test to assess for \ngallstones in patients with \nintact gallbladder.  \n\uf0a7 \nOn admission only if \ndiagnosis is uncertain and \nno alternative diagnosis is \nmore likely \n\uf0a7 \nCT within 72 hours of \nsymptom onset may \nunderestimate severity and \nmay not detect necrosis \n\uf0a7 \nNot routinely indicated in mild \nAP \n\uf0a7 \nMRI or EUS can be used to \nevaluate for retained \ncholedocholithiasis depending \non the clinical scenario \n\uf0a7 \nCan evaluate for \ncholelithiasis, \ncholedocholithiasis, or \nampullary mass \n\uf0a7 \nEUS is most helpful \nduring the outpatient \nevaluation \n\uf0a7 \nEmergent: for ascending \ncholangitis + \n\uf0a7 \nUrgent: for treatment of \ncholedocholithiasis \n+Recommendations based on high quality evidence \n \n", "4 \n \nCopyright \u00a92021. The Ohio State University. All rights reserved. This document may be used for noncommercial educational and noncommercial (NOT funded by a commercial entity) research use only. OSUWMC Clinical \nPractice Guidelines may not be reproduced, displayed, modified, or distributed in any form without a written agreement with The Ohio State University Technology Commercialization Office. Requests can be directed \nto Technology Commercialization Office (TCO) or email innovate@osu.edu \n \n \n \n \nLocal Complications/Fluid Collections \nThe management of peripancreatic fluid collections is beyond the scope of this guideline.  Due to the complexity of these clinical scenarios, treatment \nplans should be developed by a multidisciplinary team. \n \n< 4 weeks \n\u2265 4 weeks \nInterstitial Acute Pancreatitis \nAcute peripancreatic fluid collection \n\uf0a7 \nOccur early in mild, interstitial acute pancreatitis \n\uf0a7 \nTypically sterile \n\uf0a7 \nDo not have a well-defined wall \nPancreatic pseudocyst \n\uf0a7 \nLarge peripancreatic fluid collections can develop after 4\u22126 \nweeks \n\uf0a7 \nTypically sterile \n\uf0a7 \nHave a well-defined wall and contain essentially pure fluid \n\uf0a7 \nDo not require intervention unless patient is symptomatic \nNecrotizing Acute Pancreatitis \nAcute necrotic collection \n\uf0a7 \nOccur early in severe acute pancreatitis with necrosis of the \npancreatic or extrapancreatic tissue \n\uf0a7 \nHeterogenous appearance and do not have a well\u2212defined wall  \n\uf0a7 \nDoes not require prophylactic antibiotics \n\uf0a7 \nEarly intervention can be detrimental to the patient \nWalled off pancreatic necrosis \n\uf0a7 \nAcute necrotic collection can progress into this after 4\u22126 weeks \n\uf0a7 \nHave a well\u2212defined wall and contains variable amounts of \ndebris \no Solid components are best seen on MRI \n\uf0a7 \nIntervention is reserved for symptomatic patients \n", "5 \n \nCopyright \u00a92021. The Ohio State University. All rights reserved. This document may be used for noncommercial educational and noncommercial (NOT funded by a commercial entity) research use only. OSUWMC Clinical \nPractice Guidelines may not be reproduced, displayed, modified, or distributed in any form without a written agreement with The Ohio State University Technology Commercialization Office. Requests can be directed \nto Technology Commercialization Office (TCO) or email innovate@osu.edu \n \nPotential Etiologies \nRecommendations \n Discharge Planning \nGallstones (40\u221270%) \n\uf0a7 \nStrongly consider diagnosis if ALT is \u2265 3x ULN (PPV 95%) \n\uf0a7 \nFor mild gallstones/pancreatitis:  \no \nRecommend same admission cholecystectomy + \n\uf0a7 \nFor severe gallstone pancreatitis including necrosis:  \no \nDelay cholecystectomy for 4 weeks and consider \nsphincterotomy if patient is a poor surgical candidate \n\uf0a7 \nSame admission cholecystectomy is recommended \nfor mild gallstone pancreatitis+ \nAlcohol (25\u221235%) \n\uf0a7 \nCheck PETH \n\uf0a7 \nFollow CIWA protocol and provide supportive care  \no \nSee OSUWMC Alcohol Withdrawal CPG \n\uf0a7 \nSocial work consult \n\uf0a7 \nPlan for sobriety \n\uf0a7 \nVery high recurrence of AP with continued ETOH \nabuse, especially when combined with smoking \nMetabolic (1\u22124%): \nHypertriglyceridemia \n\uf0a7 \nConsider as etiology of AP if TG > > 1,000 mg/dL \n\uf0a7 \nGoal of treatment is to reduce TG to <500 mg/dL \n\uf0a7 \nNPO status may reduce TG by 40% within 24 hours  \n\uf0a7 \nPlasmapheresis is not routinely indicated, and has similar \noutcomes to NPO +/- insulin infusion \n\uf0a7 \nConsider Endocrinology consultation  \n\uf0a7 \nStart triglyceride lowering regimen prior to discharge.  \nSee Management of Hypertriglyceridemia Clinical \nPractice Guideline. \n\uf0a7 \nEndocrine or lipid clinic and PCP follow-up \nMetabolic (1\u22124%): Hypercalcemia \n\uf0a7 \nAvoid LR resuscitation (contains calcium) \n\uf0a7 \nWorkup underlying cause \n\uf0a7 \nConsider Endocrinology consultation \n \nIdiopathic \n\uf0a7 \nObtain phosphatidylethanol level during pancreatitis attacks \nto exclude alcohol use \n\uf0a7 \nRequires follow-up in Pancreas Clinic \nAutoimmune \n\uf0a7 \nThis is a rare etiology \n\uf0a7 \nNo need to check IgG4 levels as an inpatient \n\uf0a7 \nRequires follow-up in Pancreas Clinic \nDrug Induced \n\uf0a7 \nStop offending medications \n\uf0a7 \nIf pharmacologic support is still required, replace old \nmedications with those less likely to cause pancreatitis \n \nAll Patients  \n\uf0a7 \nAdequate nutritional intake (PO or other arrangements) \n\uf0a7 \nAlcohol and tobacco free indefinitely \n\uf0a7 \nControl of GI symptoms: \no \nConsider exocrine insufficiency (steatorrhea) \no \nConsider endocrine insufficiency (diabetes) \n  \n+ Recommendation is based on high quality evidence. \n", "6 \n \nCopyright \u00a92021. The Ohio State University. All rights reserved. This document may be used for noncommercial educational and noncommercial (NOT funded by a \ncommercial entity) research use only. OSUWMC Clinical Practice Guidelines may not be reproduced, displayed, modified, or distributed in any form without a written \nagreement with The Ohio State University Technology Commercialization Office. Requests can be directed to Technology Commercialization Office (TCO) or \nemail innovate@osu.edu \n \nReferences \n\u2022 \nAmerican College of Radiology. ACR Appropriateness \nCriteria\u00ae Acute Pancreatitis. Available at: \nhttps://acsearch.acr.org/docs/69468/Narrative/. \nAccessed January 31, 2022. \n\u2022 \nBadalov N, et al. (2007). Drug-induced acute pancreatitis: \nan evidence-based review. Clinical Gastroenterology and \nHepatology, 5:648-661. \n\u2022 \nBakker OJ, et al. (2014). Early versus on-demand \nnasoenteric tube feeding in acute pancreatitis. New \nEngland Journal of Medicine, 371:1983-93. \n\u2022 \nda Costa DW, et al. (2015). Same-admission versus \ninterval cholecystectomy for mild gallstone pancreatitis \n(PONCHO): a multicentre randomised controlled trial. \nLancet, 386:1261-68.  \n\u2022 \nEckerwall GE, et al. (2007). Immediate oral feeding in \npatients with mild acute pancreatitis is safe and may \naccelerate recovery\u2014a randomized clinical study. Clinical \nNutrition, 26:758-763. \n\u2022 \nJablonska B, Mrowiec S. (2021). Nutritional support in \npatients with severe acute pancreatitis-current standards. \nNutrients, 13(5):1498. \n\u2022 \nVaughn VM, et al. (2017). Early versus delayed feeding in \npatients with acute pancreatitis: a systematic review. \nAnnals of Internal Medicine, 166(12):883-892. \n\u2022 \nVege SS, et al. (2018). Initial medical treatment of acute \npancreatitis: American Gastroenterological Association \ninstitute technical review. Gastroenterology, 154:1103-\n1139. \n\u2022 \nde-Madaria E, et al. (2023). Aggressive or moderate fluid \nresuscitation in acute pancreatitis. New England Journal \nof Medicine, 387:989-1000. \n\u2022 \nWu BU, et al. (2013). Clinical management of patients \nwith acute pancreatitis. Gastroenterology, 144:1272-81. \n\u2022 \nWu BU, Conwell DL. (2012). Acute pancreatitis part II: \napproach to follow-up. Clinical Gastroenterology and \nHepatology, 8:417-422. \n\u2022 \nWu BU, Hwang JQ, Gardner TH, et al. (2011). Lactated \nRinger\u2019s solution reduces systemic inflammation \ncompared with saline in patients with acute pancreatitis. \nClinical Gastroenterology and Hepatology, 9:710-717. \n \nQuality Measures \n\u2022 \nPatients with an abdominal CT within 0-6 hours of arrival, \n6-12 hours, and > 12 hours \n\u2022 \nPatients with an ultrasound within 72 hours of admission \n\u2022 \nPatients with abdominal MRI scans within 72 hours of \nadmission \n\u2022 \nLength of stay \n\u2022 \nPatients readmitted within 30 days \n\u2022 \nMortality rate \n\u2022 \nNumber of days patient is NPO \n \nOSUWMC Resources \n\u2022 \nOrder set GE: Acute Pancreatitis Admission \n(Supplemental) [2191] \n \nGuideline Authors and Contributors \n\u2022 \nMitchell Ramsey, MD \n\u2022 \nDa Yeon Ryoo, MD \n\u2022 \nPeter Lee, MD \n\u2022 \nJennifer Knight Davis, MD \n\u2022 \nZarine Shah, MD \n\u2022 \nTessa Crilley, APRN-CNP \n\u2022 \nKathleen Wyne, MD \n\u2022 \nAllison Alter, PharmD \n\u2022 \nSarah Holland, RD \n\u2022 \nTessa Crilley, APRN-CNP \n \nPrevious Authors \n\u2022 \nPhilip Hart, MD \n\u2022 \nDarwin Conwell, MD \n\u2022 \nAndrei Manilchuk, MD \n \n \nGuideline Approved \n \nApril 27, 2022  5th Edition. Rev. 3 (5.2024) \n \n \n \nDisclaimer: Clinical practice guidelines and algorithms at The \nOhio State University Wexner Medical Center (OSUWMC) are \nstandards that are intended to provide general guidance to \nclinicians. Patient choice and clinician judgment must remain \ncentral to the selection of diagnostic tests and therapy. \nOSUWMC\u2019s guidelines and algorithms are reviewed \nperiodically for consistency with new evidence; however, new \ndevelopments may not be represented. \n"], "metadatas": [{"source": "predefined-pdfs/AcutePancreatitis.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T06:27:19.079228", "filename": "AcutePancreatitis.pdf"}, {"source": "predefined-pdfs/AcutePancreatitis.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T06:27:19.079256", "filename": "AcutePancreatitis.pdf"}, {"source": "predefined-pdfs/AcutePancreatitis.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T06:27:19.079262", "filename": "AcutePancreatitis.pdf"}, {"source": "predefined-pdfs/AcutePancreatitis.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T06:27:19.079265", "filename": "AcutePancreatitis.pdf"}, {"source": "predefined-pdfs/AcutePancreatitis.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T06:27:19.079267", "filename": "AcutePancreatitis.pdf"}, {"source": "predefined-pdfs/AcutePancreatitis.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T06:27:19.079269", "filename": "AcutePancreatitis.pdf"}]}